ALLR Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. (ALLR) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $0.25 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -2.8% since its last earnings release on August 14, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Allarity Therapeutics, Inc.
Allarity Therapeutics Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel oncology therapeutics together with drug-specific DRP(R) companion diagnostics for personalized cancer care. Allarity Therapeutics Inc. is based in Cambridge, MA U.S.A.
Sector
Healthcare
Industry
Biotechnology